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Background: Subcutaneous panniculitis-like T cell lymphomas represent a rare and difficult to diagnose entity of
cutaneous T cell lymphomas. SPTL affects predominantly young adults and presents with multifocal subcutaneous
nodules and frequently associated autoimmune features. The pathogenesis of SPTL is not completely understood.
Methods: The aim of this study was to unravel molecular pathways critical to the SPTL pathogenesis. Therefore,
we analyzed 23 skin samples from 20 newly diagnosed SPTL patients and relevant control samples of adipose and
non-malignant panniculitis tissue by using gene expression microarray, quantitative PCR, and two-colour
immunohistochemistry.
Results: Interestingly, indoleamine 2,3-dioxygenase (IDO-1), an immunotolerance-inducing enzyme, was among
the most highly overexpressed genes in all comparisons. The expression of Th1-specific cytokines, known to be
associated with autoimmune inflammation (i.e. IFNG, CXCR3, CXCL9, CXCL10, CXCL11, and CCL5), were also significantly
increased. Confirmed using immunohistochemistry, the morphologically malignant lymphocytes expressed CXCR3 and
CXCL9. IDO-1 expression was found both in some morphologically malignant lymphocytes rimming the adipocytes
and in surrounding CD11c− CD68− cells but not in CD11c+ dendritic cells in the microenvironment. The proportion of
FoxP3+ cells in SPTL exceeded that in the benign panniculitis samples.
Conclusions: Our results indicate that the up regulation of the tolerogenic IDO-1 together with the up regulation
of IFNG, CXCR3 ligands, and CCL5 are features of SPTL lesions. We anticipate that the IFNG-inducible IDO-1
expression contributes to the formation of an immunosuppressive microenvironment, favorable for the
malignant T cells. This study provides a relevant molecular basis for further studies exploring novel therapeutic
means for subcutaneous T cell lymphoma.
Keywords: Subcutaneous panniculitis-like T-cell lymphoma, IDO-1, Immunosuppressive tumor microenvironment,
Th1-type* Correspondence: pilvi.maliniemi@helsinki.fi
1Department of Dermatology and Allergology, University of Helsinki and
Helsinki University Central Hospital, Helsinki, Finland
Full list of author information is available at the end of the article
© 2014 Maliniemi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Maliniemi et al. Orphanet Journal of Rare Diseases  (2014) 9:160 Page 2 of 15Background
Subcutaneous panniculitis–like T-cell lymphoma (SPTL,
ORPHA86884) represents a rare entity of T-cell lymph-
omas. The pathomechanism of SPTL is not known but
mostly SPTL has a favourable prognosis and it responds
to non-aggressive (immunosuppressive) therapy. The most
recent WHO-EORTC classification, together with the
EORTC Cutaneous Lymphoma Group Report, confine
SPTL to subcutaneous lymphomas with an α/β T-cell
phenotype and neoplastic T-cells expressing CD3, CD8
and cytotoxic proteins (GZMB, TIA-1, perforin) [1].
In a recent joint study by the EORTC Cutaneous
Lymphoma Group [1], the main clinical, histopathological,
and prognostic features of SPTL were defined in a long-
term collection of 83 European SPTL cases. The clinical
characteristics of SPTL include multifocal, nodular skin le-
sions or deeply seated plaques involving the legs, arms,
and trunk, and less commonly the face. Ulcerations are
uncommon. B-symptoms (fever, weight loss) or laboratory
abnormalities are encountered in about half of the cases.
The most common laboratory abnormalities include vari-
ous cytopenias and elevated liver function tests. Auto-
immune diseases are common among SPTL patients [2,3],
as 20% of the patients in the European cohort had an asso-
ciated autoimmune disorder, most commonly systemic
lupus erythematosus (SLE) and some cases were first mis-
diagnosed as lupus panniculitis (lupus profundus) [1]. His-
tologically, SPTL is characterized by lobular panniculitis
with a subcutaneous atypical lymphocyte proliferation
rimming the adipocytes. The characteristic immunophe-
notype of the neoplastic cells is CD3+, CD4-, CD8+,
CD30-, and CD56-. Cytotoxic proteins (TIA-1, GZMB,
perforin) are usually strongly expressed. The prognosis of
SPTL is favourable, with a 5-year survival of 91% (82% if
hemophagocytic syndrome is present).
No previous studies on the pathomechanism of SPTL
exist, possibly due to the fact that the incidence of SPTL is
0.9% of all CTCLs [4] and therefore it is extremely difficult
to gain access to fresh subcutaneous fat tissue biopsies
prior to treatment in these rare but young patients. We
now report on the gene expression profile of fresh, un-
treated, and dissected SPTL skin lesions with Human
Exon 1.0 microarray, and subsequent confirmatory quanti-
tative RT-PCR, and immunohistological results on the cel-
lular origin of the deregulated genes. For the first time, the
molecular signature characteristic of inflammation in
SPTL is revealed.
Methods
Patient material
Altogether, the study included 20 SPTL patients from
three different European nations (Table 1), of whom four
pre-treatment skin samples were analyzed by gene ex-
pression microarray, five samples by quantitative RT-PCR, and 23 samples by immunohistochemistry (IHC).
Of one of the patients included in the array analysis, also
an affected inguinal lymph node was biopsied and avail-
able for immunohistochemistry. Additionally, three Finnish
SPTL patients were followed during treatment with oral
prednisolone and low-dose methotrexate (Table 1) and
altogether, a set of eight follow-up skin samples were ob-
tained and analysed with the microarray. The demographic
details of the patients are given in Table 1 and clinical pres-
entation of lesions in Figure 1.
For the microarray analysis, fresh subcutaneous tissue
samples were successfully obtained from four patients
with newly diagnosed SPTL (cases 1–4, Table 1). The first
samples were taken at the time of diagnosis, before any
treatment (pre-treatment), together with a sample for TCR
(T-cell receptor) rearrangement analysis (http://www.hus.
fi/sairaanhoito/laboratoriot/Sivut/default.aspx). The follow-
up samples were first obtained three to six months after
the start of systemic treatment (treatment1) and second
follow-up samples six to 12 months after the initiation of
the therapy (treatment2) when a complete clinical response
was reached (biopsy from the region of pre-existing le-
sions). In addition, one treatment1 sample was obtained
from a patient (case 5, Table 1) with no matching pre-
treatment or treatment2 sample. The control RNA for
microarray studies consisted of two samples from normal
subcutaneous fat tissue (FAT1 and −2, derived from pa-
tients undergoing dermatologic surgery) and two cases of
non-malignant panniculitis, erythema nodosum (EN1 and
−2). The study was approved by the Medical Ethical Review
Board of Helsinki University Central Hospital.
For the confirmatory immunohistological studies six
cases of lupus erythematosus profundus (LEP, i.e. lupus
panniculitis), and 13 cases of EN were included. All LEP
controls were female (mean age 38.3 years) and two
(=33%) of them had a pre-existing collagenosis with im-
munosuppressive therapy (steroids and hydroxychloro-
quine). Eleven of 13 (85%) EN cases were female (mean age
37.9 years). In seven (54%) cases the etiology of EN was an
infection (Yersinia in 67% of them), in two (15%) EN was
the first symptom of a systemic disease (colitis ulcerosa and
sarcoidosis), and in four, the etiology remained uncertain
regardless of thorough examinations. All of the samples
were taken prior to immunosuppressive treatment (except
for the two LEP cases with a pre-existing collagenosis).
RNA extraction
The fresh, skin biopsies were immediately immersed in
RNALater™ (RNA Stabilization Reagent, Qiagen, Valencia,
CA) and stored at −20/70°C. The subcutis and the deeper
dermis of the skin biopsy were dissected for the RNA iso-
lation, which was performed with RNeasy Mini Kit/
RNeasy Lipid Tissue Mini Kit (Qiagen) according to man-
ufacturers’ instructions. In SPTL samples, the amount of
Table 1 Clinical presentation, treatment and outcome of the 20 subcutaneous panniculitis-like T-cell lymphoma (SPTL) patients studied
Case Sex and
age*
First clinical presentation Clinical picture,
concomitant
diseases*
Abnormal laboratory findings Therapy Outcome PE
1 F15 In 2006 first sub-cutaneous lesion
laterally on trunk, a year later ca.
50 widespread subcutaneous
nodules, SPTL diagnosis in 05/2008
No B-symptoms CT normal, mild
splenomegaly
(diam. 13 cm)
06/2008 prednisolone CR since 06/2010;
07/2011 a solitary
MF lesion
Otherwise healthy No ANA/ ENA/DNA
antibodies
60 mg/d (2 weeks), slowly tapering
until 03/2009, and 09/2008 MTX
10 mg/wk until 02/2010→ CR
TCR clonality + in skin lesion
(2008), LD marginally elevated
232 U/l (normal range
115–235 U/l) at the time
of diagnosis
relapse 05/2010→MTX
7,5 mg/wk→ CR
2 M27
(case 8
in [5]
Subcutaneous nodules in forehead
and scalp (horse shoe shape) in
2005, SPTL diagnosis 12/2006
No B-symptoms Cervical, thoracic and
abdominal CT normal
01/2007 prednisolone CR since 02/2008
Cervical lymph nodes
enlarged (since
mononucleosis
years earlier )
BM normal 60 mg/d (2 weeks) for
3 weeks→ CR
→ reactive histology ANA-ab 320 (centromeric staining),
ENA-ab positive but specific RNP-,
SSA-, SSB- and Sm-abs negative
04/2007 prednisolone
80 mg/d until 01/2008→ CR
3 F66 09/2003 small, reddish papules in
upper and lower extremities and
nodules on shoulders; histology
in 2004: lupus erythematosus
profundus; treated with
hydroxychloroquiine 300 mg/d
(06-12/2005), dapsone 50 mg/d
(01-04/2008) with no response
Hypertension,
dyslipidemy
Thrombocytosis, leukopenia
since 1999→ BM normal,
chromosomes normal
05/2008 prednisolone CR since 03/2011
Photosensitivity→
photoprovocation
negative
→ no specific diagnosis 60 mg/d (2 weeks) decreasing until
12/2008→ CR, relapse 01/2009 –
06/2009 MTX10 mg/wk, prednisolone
40 mg /d (2 weeks) decreasing until
04/2010→ CR, relapsing disease
Low CD4 levels in 2008: 0,065 -
0,150/17-23% (normal range
0,458-1,406 E9/l/29-59%)→
sulfatrimetoprim prophylaxis
12/2009 – 02/2011 bexarotene
225 mg/d**→ initially PR, then PD
SPTL diagnosis in 05/2008 No ANA, ENA or DNA antibodies 02/2011 prednisolone 10 mg/d +
MTX 5 mg/wk maintenance→ CR
TCR clonality + in blood (07/2008)
and in MB (12/2009), LD slightly
elevated 248–380 U/l in
05/2009 – 01/2011
CT normal
4 M 47 Subcutaneous tender nodules
on buttock (15 cm) and trunk in
WBC 2,6 x 109/l, B-Ly 0,88 x
109/l (33%), B-T-CD4 0,271 x
Prednisolone 80 mg/d
for one week, then
CCR after 3 months,
all laboratory values
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Table 1 Clinical presentation, treatment and outcome of the 20 subcutaneous panniculitis-like T-cell lymphoma (SPTL) patients studied (Continued)
10/2013, SPTL diagnosed
in 2/2014
Fatigue, daily fever up to
38,5C, cough, joint pains;
no concomitant diseases
109/l, CRP 11, total ENA abs
1,6 (ref. <0,7)
50 mg/d for
1,5 months
normalized (ALT 79),
patient returned
back to work
BM normal, TCR clonality in
lymph node, ALP 109, ALT
545, LD 1162 U/l, CT : few
1 cm lymph nodes in right
axilla and left inguinal, liver
slightly enlarged 16 cm
- > 30 mg/d
5 F 60
case 7
in [5]
Subcutaneous, firm nodules
on fore-head (1 cm) and on
upper extremities (blueish) in
2005; SPTL diagnosis in 12/2006
No B-symptoms, no
enlarged lymph nodes
CBC normal, LD ad 299 U/l
until 06/2009, thereafter
normalized
03/2007 EB
therapy→ PR,
06/2007
prednisolone
60 mg/d (2 weeks)
decreasing doses
until 11/07→ CR
PR
Psoriatic arthropathy treated
with leflunomide 20 mg/d
05/2003 – 12/2006
No ANA, ENA or DNA abs,
M-component in serum,
decreased during follow-up
03/2008
prednisolone
Hypertension Dyslipidemy Thoracic and cervical
CT normal
60 mg/d (2 weeks)
decreasing doses
until 12/2009→ PR
12/2008 MTX
7,5 mg – 12,5
mg/wk→ stopped
10/2010→ PR
10/2010 bexarotene
225 mg/d→
stopped 02/2011
(ALT elevation 110
U/l)→ initially PR
then PD
05-
06/
2011 EB therapy→ SD, 08-11/2011
CHOP→ PR
6 F39 Subcutaneous, firm nodules in upper
and lower extremities, and trunk in
2008; 2/2010 lobular panniculitis in
biopsy, 5/2011 SPTL histologically
No B-symptoms, no
enlarged lymph nodes;
some joint pains
concomitantly,
hypothyreosis
since years
CBCnormal; no ANA, ENA,
DNA , TPO or Thygl abs, RF
59 IU/ml (reference 0–14),
LD normal; CT normal
8/2011 prednisolone 20– 60
mg/d→ CR , relapse in 8/2012,
whereafter prednisolone 15
mg/d + MTX 12,5 mg/wk→ CR
CR in 1/2013
7 F14 case
9 in [5]
Subcutaneous nodules in abdominal
region, lower and upper extremities
in 01/2006, SPTL diagnosis in 02/2007
No B-symptoms, no
enlarged lymph nodes
CBC normal at the time of
diagnosis, thereafter mild
anemia (Hb 110–120 g/l)
02/2007 prednisolone CR since 09/2009
Atopic constitution No ANA, ENA or DNA antibodies 40 mg/d for 1,5 months→ CR
(thereafter spontaneously
resolving lesions)LD slightly elevated (242) U/l)
at the time of diagnosis,
thereafter normalized
Thorax CT normal
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Table 1 Clinical presentation, treatment and outcome of the 20 subcutaneous panniculitis-like T-cell lymphoma (SPTL) patients studied (Continued)
8 F61 SPTL diagnosis in 03/2001,
involvement of both
lower legs
Multiple analgetic
intolerance
LD slightly elevated 236 U/l Initial therapy: radiation therapy
and CHOP 6 cycles→ CR,
relapse in 2004, bexarotene
and steroids from 2004→ PR/SD
SD
9 F77 SPTL diagnosis in 09/2007,
involvement of extremities
and thoracic area
Liver cysts, uterine myoma LD slightly elevated 259 U/l Encapsulated doxorubicin 8
cycles + prednisolone→ PR
DOD 05/2009
IFNα 3 x 6 mio
Radiation right thigh 36 Gy
Thoracic lesions: triamcinolone
intralesional
14 F68 07/2011, two nodular lesions
of the lower limb and a nasal
tumor. SPTL confirmed 09/2011
Weight loss, asthenia and
fever. Splenomegaly and
adenopathies. history of
vasculitis between 1994
and 2007
Cytopenia (lymphopenia
and thrombocytopenia),
elevated liver enzymes,
LD >2 N, b2microglobulin
7 mg/L
Chemotherapy with etoposide
(08/2011), followed by CHEP
(09/2011-10/2011) and CHOP
(11/2011-02/2012).
CR since 03/2012.
15 M*** [6] In 02/2007, three plaques on
the left and right upper limb
(5-10 cm), and face; diagnosis
confirmed in 06/2007
Fever, asthenia,
hepatomegaly and
splenomegaly, macrophage
activation syndrome
LD >2 N, elevated liver
enzymes, ANA and anti
SSA +, TCR clonality + .
Corticosteroid and
cyclosporine A
(2007–2010)
CR in 03/2008
without relapse.
16 F22 Medical history of cytophagic
and histiocytic panniculitis in
1993, treated with corticosteroid.
SPTL diagnosed in 2000,
widespread plaque and nodule
lesions on upper and lower
limbs, trunk and face.
Fever, weight loss, asthenia,
hepatomegaly and
splenomegaly. Macrophage
activation syndrome.
LD >2 N. No ANA abs,
b2microglobulin
>7 mg/L
Chemotherapy with autologous
stem cell transplantation in
2001, relapse in 2001.
Corticosteroid and MTX
between 2002 and
2008 - > CR
CR in 11/2002,
no relapse.
17 F37 EN in 2010. In 01/2011, 8
nodules on trunk and face.
SPTL diagnosed in 04/2011.
Asthenia, myalgia
and diarrhea.
Lymphopenia, No ANA
abs, TCR clonality +
Hydroxychloroquine
in 07/2011
CR in 10/2011,
no relapse.
18 M48 AL amyloidosis in 07/2007
(chemotherapy + autologous
stem cell transplantation).
In 04/2011, 3 nodules (lower
limb,trunk). SPTL confirmed
in 09/2011
Adenopathies,
hepatomegaly
and splenomegaly
Leukopenia, anemia,
thrombocytopenia,
TCR clonality +
Cyclophosphamide, adriamycin,
vincristine and methylprednisolone
in 09/2011.
PR, deceased in
04/2012 (infectious
pneumopathy)
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Table 1 Clinical presentation, treatment and outcome of the 20 subcutaneous panniculitis-like T-cell lymphoma (SPTL) patients studied (Continued)
19 F50 Multiple nodules of the upper
and lower limbs and trunk in
01/2011. SPTL confirmed
in 02/2011
- Elevated liver enzyme
and LD.
Corticosteroid in 04/2011 CR in 07/2011
20 F15 One isolated nodule (>10 cm) of
the lower limb in 12/2011. SPTL
confirmed in 04/2012
Fever, asthenia, weight
loss, adenopathy
Leucopenia, lymphopenia,
elevated LDH. TCR clonality +
Corticosteroid (05-06/2012),
vinblastine 05/2012), multiple
courses of chemotherapy
since 06/2012
PR in 01/2013
(Clinical details of cases 10–13, all in remission, are reported in [5], in Table 1 as cases 3–6).
=*at the time of diagnosis.
**Since Mehta and coworkers recently reported promising results of bexarotene therapy in SPTL, [7], bexarotene was used for the treatment of three of our patients: cases 3, 5 and 7. Only case 7 remained in long-
lasting remission with a combination therapy of bexarotene and steroids, and cases 3 and 5 reached only a temporary initial partial response [5].
***Case 15 reported first in [6] at the age of 9 months.
CT = computed tomography, LD = lactate dehydrogenase, mtx =methotrexate, CR = complete remission, PR = partial remission, MF =mycosis fungoides, ANA = antinuclear antibody, ENA = extractable nuclear antigen,
BM = bone marrow, PD = progressing disease, SD = stable disease, CBC = complete blood count, WBC = white blood cells, RBC = red blood cells, ALP = alkaline phosphatase, ALT = alanine aminotransferase, EB = electron
beam radiation therapy, CHOP = cyclophosphamide, doxorubisine, oncovine, prednisolone, IFN = interferon, DOD = died of disease.
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Figure 1 Clinical presentation of SPTL lesions. Representative
SPTL lesions before (a, d), during (b), and after (c, e) systemic
steroid +/− methotrexate treatment. For treatment details see
Table 1 (case 3 and 2, respectively).
Maliniemi et al. Orphanet Journal of Rare Diseases  (2014) 9:160 Page 7 of 15malignant T-cells was over 50% of the mononuclear cell
infiltrate, based on cytomorphology in histopathological
analysis.
Hybridization to affymetrix exon array
The RNA used was intact and of high quality (RIN 8.0-
10), as confirmed with Agilent 2100 Bioanalyzer at the
Biomedicum Helsinki Functional Genomics Unit (FuGU,
http://www.helsinki.fi/fugu/). The gene expression arrays
(Human Exon 1.0ST, Affymetrix) were performed at FuGU
according to manufacturer’s instructions. Microarray data
are available in the ArrayExpress database [www.ebi.ac.uk/
arrayexpress] under accession number E-MTAB-910. (User-
name: Reviewer_E-MTAB-910, Password: wiknooqq, Ex-
periment E-MTAB-910).
Analysis of the microarray data
Data from microarrays were pre-processed using back-
ground correction and quantile normalization [8]. For
each gene, probe set intensities were summarized to ob-
tain a single expression value. Differential expression
analysis was done for the following comparisons: (1)
pre-treatment SPTL (n = 4) vs. normal subcutaneous fat
tissue (n = 2), (2) pre-treatment SPTL (n = 4) vs. EN (n =2), and (3) pre-treatment SPTL (n = 4) vs. combined
controls (aforementioned normal subcutaneous fat tissue
and EN; n = 4). In each comparison, genes with median
fold change (FC) >4 (<0.25) and p-value of t-test <0.05
were considered as differentially expressed. Data analysis
was done using the Anduril bioinformatics framework
[9]. Due to the small number of samples available for
this rare disease, false discovery correction for p-values
was not used. Rather, the key findings were confirmed
with qRT-PCR and immunohistochemistry.
Relative quantification of gene expression
We confirmed the expression of three relevant genes,
CXCR3, IDO-1, and IFNG by quantitative RT-PCR. The
SPTL RNA samples (n = 5) were extracted either from fresh
RNA later stabilized skin tissues (cases 2–3 in Table 1 used
also in the arrays) or from formalin-fixed-paraffin-embed-
ded (FFPE) skin tissues (cases 1, 5–6 in Table 1, NucleoSpin
FFPE RNA 740969.10 Macherey-Nagel GmbH, Germany)
according to manufacturer’s instructions. Three EN RNA
samples were used in qRT-PCR as reference tissue. Two
samples were the same used in the arrays (EN1 and EN2)
and the third was extracted from the FFPE sample. The
reverse transcription into cDNA was performed using
SuperScript® VILO cDNA Synthesis kit (11754–050, Invi-
trogen). We used the following Taqman Assays (IDO-1;
Hs00984148_m1, 66 bp n = 5, IFNG; Hs00989291_m1,
73 bp n = 4, CXCR3; Hs00171041_m1, 111 bp n = 4) and
iQ Supermix (170–8860, Bio-Rad) and LightCycler 1.5
System (Roche) for the amplifications. The size and the
purity of the amplicons were checked with agarose gel
electrophoresis (2,5% SeaKem® LE agarose, Rockland, ME
USA 1xTBE). The relative expression levels were normal-
ized to reference gene GAPDH (Taqman assay 4310884E,
118 bp) and further compared to expression levels in ref-
erence tissue, erythema nodosum according to 2-ΔΔCP-
method [10].Immunohistochemistry and confocal microscopy
As part of routine diagnostics at the Dermatopathology
laboratory of Helsinki University Central Hospital, all
tissue samples were immunostained for the following
markers (manufacturer and dilutions given in paren-
thesis): CD3 (Novocastra, New Castle, UK; 1:100), CD4
(Novocastra; 1:150), CD5 (Novocastra; 1:25), CD7
(Novocastra; 1:100), CD8 (Novocastra; 1:25), CD30
(Dako, Glostrup, Denmark; 1:25), CD56 (Zymed, South
San Fransisco, CA, USA; 1:50), GZMB (Monosan, Uden,
The Netherlands; 1:100), TIA1 (Biocare, Birmingham, UK;
1:200), Ki-67 (MIB-I antibody, Dako, Glostrup, Denmark;
1:50), and TCR alpha/beta (GeneTex, TX, USA; 1:100) ac-
cording to the manufacturers’ instructions, and visualized
with DakoEnvision (Glostrup, Denmark).
Maliniemi et al. Orphanet Journal of Rare Diseases  (2014) 9:160 Page 8 of 15Additionally, immunohistochemical (IHC) detection of
the following proteins CXCL9 (Abcam, Cambridge, UK;
1:500), IL2RB (Abcam, 1:200), IDO-1 (Chemicon Inter-
national Inc. USA; 1:100, clone MAB5412), FoxP3 (Spring-
Bioscience; 1:50 clone SP97), and CXCR3 (Abcam, 1:500),
was performed according to the manufacturers’ instructions
and ImmPRESS Universal Antibody (anti-mouse Ig/anti-
rabbit Ig, peroxidase) Polymer Detection Kit (Vector La-
boratories, Burlingame, California) and NovaRED (Vector
Laboratories, Burlingame, CA) or AEC (Abcam) chromo-
gens. Furthermore, double IHC stainings were performed
for CD8 (1:100)/IDO-1 (1:100), and also for CD68 (Spring
Bioscience, Pleasanton, CA, USA, 1:200)/IDO-1 (1:100) ac-
cording to the manufacturers’ instructions and using Vector
Elite PK-6101 Rabbit IgG (Vector Laboraties)/Permanent
HRP Green Kit KDB10049 (Nordic BioSite AB, Täby,
Sweden) and VECTASTAIN AP Mouse IgG Kit(Vector La-
boratories, AK-5002)/Permanent AP-Red Kit, BCB20041
(Biosite), respectively. Double IHC staining for CD8/
CXCR3 was performed using MACH2 Double Stain 2
Mouse-HRP + Rabbit-AP Polymer Detection Kit (cat.
nro 901-MRCT525-021709, Biocare Medical, Concord
California) with BCIP/NBT and AEC as chromogens,
respectively. Moreover, double immunofluorescence (IF)
staining for CD11c (Bio SB, Santa Barbara, CA, 1:50)/IDO-
1(1:100) was performed according to the manufacturers’ in-
structions and using AlexaFluor-594 anti-rabbit antibody
(red, Abcam, 1:1000) and AlexaFluor-488 anti-mouse anti-
body (green, Abcam 1:1000), respectively. Immunofluores-
cence stainings were analyzed and photographed using
Leica Confocal Microscopy (Leica Microsystems). The IHC
detection was carried out on the total of 42 FFPE tissue
samples, obtained from 20 SPTL patients (23 samples), six
cases with LEP and 13 cases of EN. For each IHC, several
technical controls were included for both positive and
negative reactions. The positive staining result was graded
as follows: − indicates <10%, +10-25%, ++ 25-50%, and +++
over 50% of the lymphocytes expressed the given marker.
Results
SPTL skin samples demonstrate up regulation of IDO-1
and Th1 type cytokines
We first compared SPTL skin samples to normal sub-
cutaneous fat tissue to exclude the effect of normal fat
gene expression. We identified altogether 968 genes dif-
ferentially expressed in untreated/pre-treatment SPTL
skin samples, out of which 589 were up regulated and
379 were down regulated. The three most strikingly
overexpressed genes in the SPTL lesions were chemo-
kine (C-X-C motif ) ligand 10 (CXCL10; fold change:
171), guanylate binding protein 5 (GBP5; FC: 78), and
indoleamine 2,3-dioxygenase (IDO-1; FC: 71). Likewise,
the expression levels of CXCL11 (FC: 41) and CXCR3
(FC: 10), were elevated. Moreover, interleukin 2 receptorβ (IL2RB; FC: 46), chemokine (C-C motif ) ligand 5
(CCL5 = RANTES; FC 35), and interferon gamma (IFNG;
FC 17) were highly expressed. The data also shows the
overexpression of perforin 1 (PRF1; FC 33), different gran-
zymes (e.g. GZMA; FC 25, GZMB; FC 23), and members
of the SLAM family (SLAMF1; FC 6, SLAMF6; FC 36,
SLAMF7; FC 29, and SLAMF8; FC 23). Interestingly, of
the TRIM family genes (TRIM59; FC 10 and TRIM14; FC
6) were upregulated in this comparison (Table 2).
We then compared the pre-treatment SPTL samples with
in silico “combined controls” of normal subcutaneous fat
tissue and non-malignant panniculitis, erythema nodosum
(EN) samples, i.e. the median values yielded by the latter
two groups. A visualization of 290 genes that are overex-
pressed between SPTL samples and combined controls is
presented as a heatmap (Figure 2a). In this comparison, the
aforementioned genes stayed overexpressed, but to a
slightly weaker extent (Table 2). Three most overexpressed
genes were IGJ, IDO-1, and CXCL10 (Table 2). To note, the
overexpression of CXCL9 (FC 20) was seen only in this
combined comparison (Table 2). Furthermore, the 99 genes
that are annotated with the Gene Ontology term “Defence
response” are visualized in a heatmap as well (Figure 2b).
When comparing SPTL samples against inflammatory
EN samples only, six genes (PRF1, KLRD1, IGJ, KIR2DS4,
GZMB, and IDO-1) showed the highest expression and
appeared equally overexpressed by 20-fold. Also, IFNG,
IL2RB, and CXCR3 stayed overexpressed but to a slightly
weaker tendency as observed earlier (Table 2). Of the
CXCR3 ligands, only CXCL11 reached significant overex-
pression in this comparison (Table 2). This would suggest
some similarity between SPTL and EN regarding the
CXCR3 pathway involved in the development of auto-
immune diseases (reviewed by [11]).
Consistent with previous findings, the expression of
GZMB gene encoding the cytotoxic protein GZMB, used
in the routine diagnostics of SPTL, was constantly ap-
proximately 20-fold overexpressed in all comparisons.
Likewise, Fas ligand (FASLG, TNF superfamily, member 6)
was equally overexpressed by 5-fold in all comparisons. In
addition, up regulation of RASGRP1, a nucleotide ex-
change factor specifically activating Ras, was observed in
SPTL samples (FC 21, FC 8, and FC 4). From the NK
gene family, only NKG7 (natural killer cell group 7 se-
quence) was overexpressed by 23-, 18-, and 14-fold, re-
spectively. Other up regulated genes in this comparison
remained in line with the other comparisons. Of the
down regulated genes, several T-box transcription fac-
tors (TBX18, TBX15) were represented. Among the
miRNA family (hsa-miR-199a-2, hsa-miR-410, hsa-miR-
487-b, and hsa-miR-3665) were down regulated by 5-
10-fold, respectively. On the other hand, miR-219-1 was
overexpressed (FC 4). The list of discussed, deregulated
genes is summarized in Table 2.
Table 2 SPTL patients show differences in the expression of selected genes compared to controls
Gene Normal fat1 Combined controls2 Inflammatory EN3 DNA
band
Gene function
FC p-value FC p-value FC p-value
CXCL10 170.1 <0.01 32.93 0.05 ns ns 4q21.1 chemokine, T-cell trafficking, ligand for CXCR3
GBP5 78.08 <0.01 28.00 0.02 ns ns 1p22.2 GTPase activity, cellular response to interferon-G
IDO1 70.57 <0.01 35.52 <0.01 17.91 0.01 8p12-11 catabolism of tryptophan, suppressor of immune response
IKZF3 63.27 0.05 24.48 0.01 10.98 0.05 17q12 B-cell activation, regulation of lymphocyte differentiation
IGJ 55.37 0.01 36.09 0.01 19.40 0.03 4q13.3 IgA and antigen binding, adaptive immune response,
CXCL9 ns ns 20.25 0.04 ns ns 4q21.1 chemokine, T-cell trafficking, ligand for CXCR3
IL2RB 45.71 <0.01 25.76 <0.01 12.49 0.01 22q12.3 cytokine receptor
CXCL11 41.41 <0.01 17.31 0.01 7.33 0.02 4q21.1 chemokine, T-cell trafficking, ligand for CXCR3
KLRD1 36.53 0.01 28.68 0.01 19.44 0.01 12p13.2 transmembrane receptor activity, innate immune response
CCL5 34.83 <0.01 18.37 0.01 ns ns 17q12 chemokine, T-cell polarization
PRF1 32.69 <0.01 26.15 <0.01 19.86 <0.01 10q22.1 calcium ion binding, cellular defense response,
SLAMF7 28,67 0.01 16.60 <0.01 9.89 0.01 1q23.3 lymphocyte activation
GZMB 22.58 <0.01 22.58 <0.01 18.57 <0.01 14q12 T-cell cytotoxicity
CCR5 25.72 <0.01 10.21 0.01 4.75 <0.01 3p21.31 chemokine receptor
NKG7 23.55 <0.01 17.73 <0.01 13.82 <0.01 19q13.41 integral component of plasma membrane
RASGRP1 20.76 0.03 8.09 0.01 4.10 <0.01 15q14 lymphocyte regulation
APOBEC3G 19.47 <0.01 9.65 <0.01 5.42 <0.01 22q13.1 innate immune response, defense response to virus
KIR2DS4 ns ns ns ns 19,01 0.05 19q13.42 innate immune response
IFNG 17.24 0.01 15.46 0.01 10.45 0.01 12q15 cytokine, immunoregulator
TNFRSF9 15.54 0.02 14.45 0.02 11.57 0.02 1p36.23 receptor, survival and development of T cells
CCL4 12.64 <0.01 8.97 0.01 ns ns 17q12 chemokine, T-cell polarization
TRIM59 9.93 0.01 5.38 0.03 ns ns 3q25.33 negative regulation of I-kappaB kinase/NF-kappaB signaling
CXCR3 9.83 0.04 6.68 <0.01 4.68 0.04 Xq13.1 chemokine receptor, recruitment of inflammatory cells
FASLG 5.00 0.01 5.38 <0.01 6.12 0.01 1q24.3 cytokine activity, T cell apoptotic process
TBX18 0.22 0.05 ns ns ns ns 6q14.3 transcription factor
TBX15 0.13 <0.01 0.19 <0.01 ns ns 1p12 transcription factor
1SPTL vs. normal subcutaneous fat, 2SPTL vs. combined controls, 3SPTL vs. inflammatory EN, ns = non-significant. FC = Fold Change. See ArrayExpress for all data.
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during the systemic therapy with prednisolone and low-
dose methotrexate, a clear transition towards normalization
of the most relevant genes, like IDO-1, was observed as
early signs of response at the time when the malignant T
cell population was still clearly detectable histologically
(Additional file 1: Figure S1).
Relative quantification of gene expression
The expression levels of three selected deregulated
genes, CXCR3, IDO-1, and IFNG were confirmed by
quantitative RT-PCR from five cases and normalized to
reference gene, GAPDH. The relative mRNA expression
levels were then compared with the levels in reference
tissue (erythema nodosum, EN) and results were pre-
sented as fold changes. IDO-1 mRNA showed overex-
pression by 30-350-fold in all SPTL samples compared
with EN (Figure 3). The cytokine receptor CXCR3showed overexpression by 10-50-fold and IFNG by 50-
150-fold compared to EN. We did not detect any CXCR3
or IFNG expression in case 5, although the GAPDH levels
were similar to other samples. Overall, the quantitative
analysis not only confirmed the expression of IDO-1 and
CXCR3 but also revealed even higher fold changes than
the microarray analyses.
Immunohistochemistry designates the cellular origin of
the deregulated gene products
To further confirm the cellular origin of the deregulated
gene products, we performed IHC of selected gene
products in an extended series of patient and control
tissue samples. IDO-1 was seen intensively expressed both
in some morphologically malignant T-cells rimming the
fat cells (Table 3, Figures 4b and 5c) as well as in nearby
CD8−CD68−CD11c− cells (Figures 5a,c,f ) [12,13], when
using double immunofluorescence. Surprisingly, IDO-1
Figure 2 Expression profiling revealed a gene expression pattern distinguishing SPTL from combined control samples. a) Visualization
of 290 genes that are overexpressed between pre-treatment (n = 4) and combined control samples (n = 4). Only the normal fat control samples
are shown. Expression values are in base-2 logarithm scale. b) Visualization of 99 genes from set a) above, annotated with the Gene Ontology
term “Defence response” (GO:0006952). Here, the erythema nodosum (EN) control samples with a similar type of tissue inflammation, but devoid
of malignant T lymphocytes, are shown in turn.
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with confocal microscopy performed on double-IF stained
sections (Figures 5f-h). We also searched for FoxP3-
positive regulatory T-cells (Tregs), since IDO-1 has been
reported to increase the proportion of Tregs in the tumor
infiltrate [14]. Approximately 25-50% of the inflammatory
lymphocytes were FoxP3-positive in SPTL samples (Figure 4f)
with abundant expression of IDO-1 (Table 3). FoxP3+
lymphocytes were found also within the inflammatory
infiltrates of EN and LEP, both with no IDO-1 expression,
but at a considerably lower frequency (Table 3).
CXCL9 and CXCR3 were chosen as markers for
CXCR3 pathway. CXCR3 protein was expressed almost
exclusively in the malignant lymphocyte infiltrates of
the SPTL samples (Table 3, Figures 4c,e, 5b). The non-
malignant inflammatory infiltrates of LEP and EN con-
trol samples expressed CXCR3 protein, too, but to a
varying extent. (Table 3, Figure 4d). CXCL9 was abun-
dantly expressed in the malignant cells of 15 SPTL sam-
ples (Figure 4a, Table 3) while notably less so in all LEP
and EN samples (Table 3). By double immunostaining
of SPTL samples for CD8 and CXCR3, we confirmed
that the malignant lymphocytes, typically rimming theadipocytes, mostly co-expressed both markers (Figures 4c
and 5b). In LEP, the CXCR3 and CD8 were not co-
expressed by the same cells (Figure 4d).
Interestingly, we could also examine the biopsies of af-
fected lymph nodes of one of the SPTL patients (case 4,
Table 1). An intense malignant T-cell infiltration, rim-
ming the fat cells in the adipose tissue surrounding the
nodes, was found. The pattern of IDO-1 and CXCR3 ex-
pression was similar to that seen in the cutaneous SPTL
lesions (Figure 5d-e), as well as FoxP3 expression (data
not shown). To conclude, markers of CXCR3 pathway,
typically involved in autoimmune diseases, were expressed
both in SPTL and in control (LEP and EN) cases, but in
SPTL, the main source of CXCL9 and CXCR3-positive
cells was the malignant, CD8+ lymphocyte infiltrate
(Table 3).
Discussion
This is the first study to explore the gene expression sig-
natures relevant for the pathogenesis of SPTL. Obtaining
fresh, lesional tissue samples of this rare lymphoma has
been challenging and therefore, the findings were vali-
dated in a larger archival material of 23 SPTL samples,
Figure 3 Relative quantification of studied gene expressions in SPTL lesions compared with reference tissue (erythema nodosum).
Relative mRNA expression of CXCR3 (white column), IDO-1 (dark grey), and IFNG (light grey) in SPTL lesions. Relative expressions are represented
as fold changes in comparison with erythema nodosum. To note, CXCR3 and IFNG genes showed no detectable expression in case 5, although
the GAPDH level was similar to other samples. All gene expression levels were normalized to reference gene, GAPDH. nd = not detected.
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such as qRT-PCR and/or single and combined IHC.
The most important and novel finding is that SPTL le-
sions are characterized by high expression of the immuno-
suppressive protein IDO-1 (Indoleamine 2,3-dioxygenase),
both by the morphologically malignant T cells in addition
to CD11c-CD68- double negative cells in the microenvir-
onment. This result is supported by the high levels ofTable 3 Protein expression of selected up regulated genes as
SPTL, lupus erythematosus panniculitis (LEP) and erythema n
Diagnosis Positivity among
SPTL morphologically malignant cells i
inflammatory infiltrate in dermis
Lupus erythematosus panniculitis (LEP) inflammatory infiltrate
Erythema nodosum (EN) inflammatory infiltrate
Number of positive cases/all cases studied.
Grading of positive immunostaining: − below 10%, +10-25%, ++ 25-50%, and +++
positive cells were not always equally distributed in the tissue sections. LEP and ENvarious inflammatory cytokines shown here, e.g. IFNG,
which is also known to induce the expression of IDO-1.
Furthermore, IDO-1 is an essential enzyme in tryptophan
catabolism, along the kynurenin pathway [15]. IDO has
been identified as a key regulator of tumor immune eva-
sion. IDO-1 has been shown to protect tumors from an at-
tack by tumor-associated, antigen-specific host cytotoxic
T cells [16]. Increased IDO expression and activity hasdetected by immunohistochemistry in tissue sections of
odosum (EN)
IDO-1 CXCR3 CXCL9 IL2RB FOXP3
n adipose tissue 14/19 15/21 15/15 9/14 0/9
++ ++ + + + + + -
11/19 2/21 4/14 9/14 7/9
++ + + + + or ++
0/5 5/5 6/6 4/6 4/5
- + + + + +
0/5 11/12 9/10 8/9 1/5
- + + + + + +
over 50% of the cells (lymphocytes) expressing the given marker. To note, the
have no morphologically malignant cells.
Figure 4 Immunohistological confirmation of the protein expression of the up regulated genes in SPTL. a) CXCL9-expressing, morphologically
mostly malignant lymphocytes in a SPTL lesion (red, 20x). b) IDO-1-expressing morphologically malignant lymphocytes (red arrow) rimming a fat cell in
a SPTL lesion (red, 20x). c) Double immunostaining for CD8 (cyan) and CXCR3 (red) showing CD8+CXCR3+ lymphocytes (red arrow) in a SPTL lesion
(20x). Cells expressing only CD8 are indicated with blue arrow. No counterstain. d) Double immunostaining for CD8 (cyan) and CXCR3 (red) showing
exclusively the expression of CD8 and CXCR3 in different cells in a LEP lesion (20x). No counterstain. a)-d) Insert in upper right corner represents
magnification of 40x. e) CXCR3-expressing malignant lymphocytes rimming the fat cell in a SPTL lesion (red, 20x). f) High number of FoxP3+ (brown)
regulatory T-cells in a SPTL lesion (red, 40x).
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hematological malignancies [17], but never earlier in
SPTL. The expression of IDO-1 also seems to decrease
the infiltration of immune cells in the tumor and in-
crease the proportion of regulatory T lymphocytes
(Tregs) in the infiltrate [14]. We found the expression
of FoxP3+ Tregs to associate with the IDO-1 expression
in SPTL.
The relationship between IDO-1-expressing tumors and
T lymphocytes is, however, complex as IFNG is a major
inducer of IDO-1 [15,18]. IFNG is a soluble cytokine, pre-
dominantly produced by the NK cells with antiviral, im-
munoregulatory, and anti-tumor properties. Its aberrant
expression is associated with several autoimmune diseases[19]. In our series, IFNG was 17-fold up regulated in SPTL
samples, and its expression lowered to 4.5-fold as a conse-
quence of ongoing therapy (Additional file 1: Figure S1).
IFNG has been shown to act in a feedback fashion to in-
duce IDO-1′s enzymatic function. This then creates an
immunosuppressive microenvironment, through the im-
munosuppressive kynurenin metabolites, leading to T cell
anergy towards the transformed tumor cells [20,21],
reviewed in [14,22].
We also found a distinct expression pattern intensify-
ing a Th1 type response through high expression of
CXCR3 and CCR5, the Th1 receptors, and their ligands
(CXCL9, CXCL10, CXCL11, CCL5, and CCL4) in SPTL.
CXCR3 is expressed on several immune cells, mainly on
Figure 5 Immunohistological specification of the immunosuppression-inducing IDO-1 in SPTL. a) Double IHC staining of CD8 (cyan) and
IDO-1 (red) shows that IDO-1 is mostly expressed in other cells than CD8+ lymphocytes in a SPTL lesion (20x). b) Here, double staining of CD8
(cyan) and CXCR3 (red) shows the expressions in same cells in SPTL as comparison (red arrow, 40x). c) Double staining of IDO-1 (red, red arrow)
and the macrophage marker CD68 (cyan, blue arrow) shows expression mainly in different cells (40x). d)-e) Perinodular fat, infiltrated with
morphologically malignant lymphocytes, surrounding an enlarged lymph node of a SPTL patient (case 4, Table 1). Similar d) IDO-1 and e) CXCR3
expression is seen as in subcutaneous SPTL lesions. f)-h) Double IF staining of CD11c (red) and IDO-1 (green) confirms that IDO-1 is not expressed
by CD11c -positive dendritic cells (Leica confocal microscopy, 40x).
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into Th1 direction but also on subset(s) of circulating hu-
man Tregs [23]. The CXCR3 ligands CXCL9, CXCL10,
and CXCL11 are members of the CXC chemokine family,
not constitutively expressed but also up regulated by e.g.
IFNG in a proinflammatory cytokine milieu. They are
expressed by T lymphocytes (CD3, CD4, and CD8 popula-
tions), and moreover, CXCL9 and CXCL10 are chemo at-
tractants for CD4+ and CD8+ T effector cells [11]. In
cutaneous LE, CXCR3 is expressed by a majority of the in-
filtrating T cells, and the three CXCR3-activating chemo-
kines are produced locally [24]. The role of CXCR3
pathway has been proven central in the development of
many autoimmune diseases, such as rheumatoid arthritis,
SLE and autoimmune thyroid diseases [25,26], reviewed
by [11]. In this study, although CXCL9 and CXCR3 were
expressed – to a varying degree – also in the inflammatory
dermatoses LEP and EN, they were mostly expressed by
the malignant lymphocytes in SPTL as shown by immu-
nohistochemistry. With double IHC we further showed
that the CD8+- malignant cells rimming the adipocytes
also expressed CXCR3.IFNG overexpression has been reported in cutaneous LE
subtypes [27] and other autoimmune diseases (reviewed in
[28]). It is thus not surprising that IFNG- induced IDO-1
has also been shown to drive autoimmunity [29]. Even a
specific IDO-1 gene SNP associates with autoimmune sys-
temic sclerosis [30]. Thus, taken together, the above dis-
cussed gene activation observed in this study strongly
suggests an autoimmune background for SPTL.
Our data also revealed other interesting genes to be over-
expressed in SPTL and related to autoimmunity. The sec-
ond most up regulated gene was GBP5 which is known to
promote NLRP3 inflammasome assembly and immunity in
mammals [31]. RASGRP1, is a nucleotide exchange factor
specifically activating the Ras pathway. It regulates the
threshold of T cell activation and antigen induced expan-
sion and controls the initiation and duration of CD8 T cell
immune responses but also activates NK cell effector func-
tions [32]. Additionally, up regulation of CCL5 (known as
RANTES), a chemokine mediating the trafficking and
homing of T cells [33], in the SPTL samples refers to a Th1
type inflammatory response [34]. Other genes, favoring
Th1 type autoimmunity, like NKG7 [34,35], IL32 [36], IL18
Maliniemi et al. Orphanet Journal of Rare Diseases  (2014) 9:160 Page 14 of 15[37], CCR1 [38], and CCR5 [39] were also overexpressed in
SPTL based on this array data. Interestingly, in the set of
follow-up samples, obtained during the systemic therapy
with prednisolone and low-dose methotrexate, the gene ex-
pression profile of the most relevant genes, like IDO-1,
clearly normalized along the diminished malignant T cell
population in the tissue.
It was recently shown in a humanized mouse model that
IDO-expressing humanized mesenchymal stem cells
(MSC-IDO) were capable of suppressing T-lymphocyte
proliferation and promoting tumor growth in melanoma
and lymphoma tumor models [40]. Importantly, this effect
was reversed by the IDO inhibitor 1-methyl-tryptophan.
Thus, our finding of significantly elevated IDO-1 expres-
sion in SPTL compared to EN and LEP, is essentially im-
portant and of clinical relevance since novel specific IDO
inhibitors [41] are already in early clinical testing.
Conclusions
Our findings indicate that an autoimmune type of inflam-
mation is likely to underlie the development of SPTL and
thus corroborate previous speculations on eventual over-
lap between SPTL and lupus erythematosus [1,3,5]. We
hypothesize that some – as yet unknown - triggering fac-
tor induces an autoinflammatory reaction with the up
regulation of IFNG, CXCR3, and CCL5. This in turn, leads
to the up regulation of IFNG-inducible IDO-1, which is
known to induce an immunosuppressive microenviron-
ment, allowing malignant cells to escape of immunological
control. This is the first study on gene and protein signa-
ture in SPTL and it provides a relevant molecular basis for
further studies in defining novel targets for future thera-
peutic efforts.
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